Who is sponsoring NCT07149597?

NCT07149597 is sponsored by Shanghai Chest Hospital.

What drugs are being tested in NCT07149597?

Interventions in NCT07149597: Mobile CBCT Three-Dimensional Scanning.

What condition does NCT07149597 study?

NCT07149597 studies Peripheral Pulmonary Lesions (PPLs).

Is NCT07149597 still recruiting?

NCT07149597 is currently not yet recruiting. Last updated 8 September 2025.

Last reviewed 2025-09-08 · How we verify

NCT07149597

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Clinical Validation Study on the Imaging Efficacy of Mobile 4D CBCT Technology for Peripheral Pulmonary Lesions

Not yet recruiting Last updated 8 September 2025

What this trial tests

trial testing Mobile CBCT Three-Dimensional Scanning in Peripheral Pulmonary Lesions (PPLs) in 50 participants. Not yet recruiting.

Timeline

1 September 2025

Primary endpoint
31 December 2025

30 June 2026

Quick facts

Lead sponsor	Shanghai Chest Hospital
Status	Not yet recruiting
Study type	OBSERVATIONAL
Enrollment	50
Start date	1 September 2025
Primary completion	31 December 2025
Estimated completion	30 June 2026
Sites	1 location across China

Drugs / interventions tested

Mobile CBCT Three-Dimensional Scanning

Conditions studied

Peripheral Pulmonary Lesions (PPLs) — all drugs for Peripheral Pulmonary Lesions (PPLs) →

Sponsor

Shanghai Chest Hospital

Who can join

18 and older, any sex, with Peripheral Pulmonary Lesions (PPLs). Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of this study is to evaluate the clinical value of mobile 4D CBCT technology in the diagnosis and treatment of peripheral pulmonary lesions and to validate its intraoperative dynamic three-dimensional CT imaging capability.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other Shanghai Chest Hospital trials

Trials by the same sponsor.

NCT07515027 — Electroacupuncture Plus 5-HT3 Receptor Inhibitor for PONV Prevention in High-Risk Patients Undergoing Thoracoscopic Lung · NA · recruiting
NCT07479628 — Neoadjuvant Adebrelimab Plus CRT for Locally Advanced Thymic Carcinoma · Phase 2 · not yet recruiting
NCT07528066 — Downstaging and RATS After Neo-Chemo-IO: Impact on Surgical Outcomes in NSCLC · recruiting
NCT07331727 — Epicardial Adipose Tissue-Targeted DApagliflozin for Reducing Electrical Remodeling in Atrial Fibrillation · NA · not yet recruiting
NCT07320768 — Renal Denervation Combined With Pulsed Field Ablation to Prevent Blanking-Period Recurrence in Persistent Atrial Fibrill · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT07149597 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Shanghai Chest Hospital
Last refreshed: 8 September 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07149597.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing